Vectibix Meets Primary Endpoint In Phase III Wild-Type KRAS Colorectal Cancer Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase III study comparing Vectibix (panitumumab) and best supportive care met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login